(Press-News.org) Sanfilippo Syndrome type A, or Mucopolysaccharidosis type IIIA (MPSIIIA), is a neurodegenerative disease caused by mutations in the gene that encodes the enzyme sulfamidase. Mutations in this gene lead to deficiencies in the production of the enzyme, which is essential for the breakdown of substances known as glycosaminoglicans. If these substances are not broken down, they accumulate in the cells and cause neuroinflammation and organ dysfunction, mainly in the brain, but also in other parts of the body. Children born with this mutation are diagnosed from the age of 4 or 5. They suffer neurodegeneration, causing mental retardation, aggressiveness, hyperactivity, sleep alterations, loss of speech and motor coordination, and they die in adolescence.
A team of researchers headed by the director of the UAB's Centre for Animal Biotechnology and Gene Therapy (CBATEG), Fàtima Bosch, has developed a gene therapy treatment that cures this disease in animal models, with pre-clinical studies in mice and dogs. The treatment consists of a single surgical intervention in which an adenoassociated viral vector is injected into the cerebrospinal fluid, the liquid that surrounds the brain and the spinal cord. The virus, which is completely harmless, genetically modifies the cells of the brain and the spinal cord so that they produce sulfamidase, and then spreads to other parts of the body, like the liver, where it continues to induce production of the enzyme.
Once the enzyme's activity is restored, glycosaminoglican levels return to normal for life, their accumulation in cells disappears, along with the neuroinflammation and dysfunctions of the brain and other affected organs, and the animal's behaviour and its life expectancy return to normal. While mice with the disease lived only up to 14 months, those given the treatment survived as long as healthy ones.
This is a joint project between the UAB and the pharmaceutical company Esteve. The study has been published in the online edition of The Journal of Clinical Investigation.
###
Gene therapy cures a severe paediatric neurodegenerative disease in animal models
2013-07-02
ELSE PRESS RELEASES FROM THIS DATE:
GIS scientists discover molecular communication network in human stem cells
2013-07-02
Scientists at A*STAR's Genome Institute of Singapore (GIS) and the Max Planck Institute for Molecular Genetics (MPIMG) in Berlin (Germany) have discovered a molecular network in human embryonic stem cells (hESCs) that integrates cell communication signals to keep the cell in its stem cell state. These findings were reported in the June 2013 issue of Molecular Cell.
Human embryonic stem cells have the remarkable property that they can form all human cell types. Scientists around the world study these cells to be able to use them for medical applications in the future. ...
Fishing in the sea of proteins
2013-07-02
To convert a gene into a protein, a cell first crafts a blueprint out of RNA. One of the main players in this process has been identified by researchers led by Dr. Jessica Jacobs at the Ruhr-Universität Bochum. The team "fished" a large complex of proteins and RNA, which is involved in the so-called splicing, from the chloroplasts of the green alga Chlamydomonas reinhardtii. This cuts non-coding regions out of the messenger RNA, which contains the protein blueprint. "For the first time, we have established the exact composition of an unknown splicing complex of the chloroplasts", ...
Changes in hyaluronan metabolism key in adaptation of keratinocytes to radiation injury
2013-07-02
As the outermost layer of skin, epidermis is crucial in forming a permeability barrier and protection against various environmental agents. Thus, investigating the biology of its most important cell type, the keratinocyte, is key to understanding the effects of solar ultraviolet radiation in skin, and helps design effective means of protection against excessive exposure. It has already previously been shown with both cell culture and in vivo animal models that UV irradiation increases the expression of hyaluronan, which is an important carbohydrate of the extracellular ...
Cadaver study may help clinicians identify patients who can skip ACL reconstruction
2013-07-02
A study by researchers at Hospital for Special Surgery has provided the first evidence that the shape of a person's knee could be a factor in the decision of whether a patient should undergo anterior cruciate ligament (ACL) reconstruction after an ACL tear. The study is published online ahead of print in the Proceedings of the Institution of Mechanical Engineering.
"This is the first study to show that after your ACL is ruptured, the changes in the mechanics of the knee can really be affected by the shape of the knee," said Suzanne Maher, Ph.D., associate director of ...
Fidaxomicin in Clostridium difficile infection: added benefit not proven
2013-07-02
The antibiotic fidaxomicin (trade name: Dificlir) has been approved in Germany since December 2011 for the treatment of adults who have diarrhoea caused by Clostridium difficile. In an early benefit assessment pursuant to the "Act on the Reform of the Market for Medicinal Products" (AMNOG), the German Institute for Quality and Efficiency in Health Care (IQWiG) examined the added benefit of fidaxomicin in comparison with current standard therapy. According to this, there is currently no proof of an added benefit. The manufacturer did not submit any studies on non-severe ...
Abiraterone: Hint of considerable added benefit
2013-07-02
Abiraterone acetate (abiraterone for short, trade name: Zytiga) has been approved in Germany since December 2012 for men with metastatic prostate cancer that is not responsive to hormone blockade, who only have mild symptoms or so far none at all, and in whom chemotherapy is not yet indicated. In an early benefit assessment pursuant to the "Act on the Reform of the Market for Medicinal Products" (AMNOG), the German Institute for Quality and Efficiency in Health Care (IQWiG) examined whether abiraterone offers an added benefit compared with the present standard therapy. ...
The ribosome -- a new target for antiprion medicines
2013-07-02
New research results from Uppsala University, Sweden, show that the key to treating neurodegenerative prion diseases such as mad cow disease and Creutzfeldt-Jakob disease may lie in the ribosome, the protein synthesis machinery of the cell. The results were recently published in the Journal of Biological Chemistry.
Prion diseases are fatal neurodegenerative diseases caused by misfolding of prion proteins. Examples of prion diseases are scrapie in sheep, mad cow disease and Creutzfeldt-Jakob disease in human.
What triggers misfolding of the prion proteins to the amyloid ...
Companies look at wrong things when using facebook to screen job applicants
2013-07-02
Employers are increasingly using Facebook to screen job applicants and weed out candidates they think have undesirable traits. But a new study from North Carolina State University shows that those companies may have a fundamental misunderstanding of online behavior and, as a result, may be eliminating desirable job candidates.
Researchers tested 175 study participants to measure the personality traits that companies look for in job candidates, including conscientiousness, agreeableness and extraversion. The participants were then surveyed on their Facebook behavior, allowing ...
Corn yield prediction model uses simple measurements at a specific growth stage
2013-07-02
The ability to predict corn yields would benefit farmers as they plan the sale of their crops and biofuel industries as they plan their operations. A new study published in the July-August issue of Agronomy Journal describes a robust model that uses easily obtained measurements, such as plant morphology and precipitation, collected specifically at the silking growth stage of the plant. The new model could help both growers and industry maximize their profits and efficiency.
Forecasting crop yield can be extremely useful for farmers. If they have an idea of the amount ...
New hardware design protects data in the cloud
2013-07-02
CAMBRIDGE, Mass -- Cloud computing -- outsourcing computational tasks over the Internet -- could give home-computer users unprecedented processing power and let small companies launch sophisticated Web services without building massive server farms.
But it also raises privacy concerns. A bank of cloud servers could be running applications for 1,000 customers at once; unbeknownst to the hosting service, one of those applications might have no purpose other than spying on the other 999.
Encryption could make cloud servers more secure. Only when the data is actually being ...